GTEx Pituitary 20-29 vs 40-49 Up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GTEx Pituitary 20-29 vs 40-49 Up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GTEx Pituitary 20-29 vs 40-49 Up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GTEx Pituitary 20-29 vs 40-49 Up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GTEx Pituitary 20-29 vs 40-49 Up.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 1291

Gene

long intergenic non-protein coding RNA 839

Gene

long intergenic non-protein coding RNA 958

Gene

SATB2 antisense RNA 1

Gene

inositol polyphosphate multikinase pseudogene

Gene

long intergenic non-protein coding RNA 2009

Gene

BMS1 pseudogene 22

Gene

cyclin Y like 2 (pseudogene)

Gene

long intergenic non-protein coding RNA 298

Gene

keratoconus gene 6

  • Gene

    long intergenic non-protein coding RNA 1291


  • Gene

    long intergenic non-protein coding RNA 839


  • Gene

    long intergenic non-protein coding RNA 958


  • Gene

    SATB2 antisense RNA 1


  • Gene

    inositol polyphosphate multikinase pseudogene


  • Gene

    long intergenic non-protein coding RNA 2009


  • Gene

    BMS1 pseudogene 22


  • Gene

    cyclin Y like 2 (pseudogene)


  • Gene

    long intergenic non-protein coding RNA 298


  • Gene

    keratoconus gene 6

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.